IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
Comments Off on IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
February 23, 2026
The Phase 2 CALMA trial expands clinical sites for cannabinoid-based therapy Alzheimer agitation, offering new hope for managing difficult symptoms. This cannabinoid-based therapy Alzheimer agitation approach targets neuroinflammation and behavioral…
Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study
Comments Off on Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study
November 16, 2021
Parkinson disease patients often seek alternative treatments like cannabidiol. This study investigates the safety and tolerability of cannabidiol in Parkinson disease. Results show mild adverse events and potential symptom improvement.
Tetrahydrocannabinol-Rich Extracts Enhance Brain Glucose Consumption and Metabolic Modulation
Comments Off on Tetrahydrocannabinol-Rich Extracts Enhance Brain Glucose Consumption and Metabolic Modulation
October 26, 2021
Tetrahydrocannabinol brain glucose consumption plays a crucial role in modulating metabolic complications linked to neurodegenerative diseases. THC-rich extracts from Cannabis Sativa L. improve glucose uptake and reduce oxidative stress in brain tissue.…